Clinical Trial Update: Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating pioglitazone plus empagliflozin for fatty liver disease in people with type 2 diabetes and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Type 2 Diabetes, Fatty Liver | Phase 4 | Status: RECRUITING